Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer

Journal of Experimental & Clinical Cancer Research

William G Hawkins⁴  Robert H Mach¹  Peter Goedegebuure⁴  Francesco Berardi²  Carmen Abate²  Dirk Spitzer³  Suwanna Vangveravong¹  John R Hornick³ 

[1] Division of Radiology, Washington University School of Medicine, St. Louis, MO, USA;Dipartimento Farmacochimico, Università degli Studi di Bari Aldo Moro, di Bari Aldo Moro, Italy;Department of Surgery, Washington University School of Medicine, S. Euclid Avenue, St. Louis, MO, USA;Alvin J. Siteman Cancer Center, Washington University School of Medicine, S. Euclid Avenue, St. Louis, MO, USA

关键词: lysosomal membrane permeablization;    caspase-3;    pancreatic cancer;    sigma-2 receptor;   

Others  :  826494
DOI  :  10.1186/1756-9966-31-41

 received in 2012-01-01, accepted in 2012-05-02,  发布年份 2012

【 摘 要 】

Background

Sigma-2 receptor ligands have been studied for treatment of pancreatic cancer because they are preferentially internalized by proliferating cells and induce apoptosis. This mechanism of apoptosis is poorly understood, with varying reports of caspase-3 dependence. We evaluated multiple sigma-2 receptor ligands in this study, each shown to decrease tumor burden in preclinical models of human pancreatic cancer.

Results

Fluorescently labeled sigma-2 receptor ligands of two classes (derivatives of SW43 and PB282) localize to cell membrane components in Bxpc3 and Aspc1 pancreatic cancer cells and accumulate in lysosomes. We found that interactions in the lysosome are critical for cell death following sigma-2 ligand treatment because selective inhibition of a protective lysosomal membrane glycoprotein, LAMP1, with shRNA greatly reduced the viability of cells following treatment. Sigma-2 ligands induced lysosomal membrane permeabilization (LMP) and protease translocation triggering downstream effectors of apoptosis. Subsequently, cellular oxidative stress was greatly increased following treatment with SW43, and the hydrophilic antioxidant N-acetylcysteine (NAC) gave greater protection against this than a lipophilic antioxidant, α-tocopherol (α-toco). Conversely, PB282-mediated cytotoxicity relied less on cellular oxidation, even though α-toco did provide protection from this ligand. In addition, we found that caspase-3 induction was not as significantly inhibited by cathepsin inhibitors as by antioxidants. Both NAC and α-toco protected against caspase-3 induction following PB282 treatment, while only NAC offered protection following SW43 treatment. The caspase-3 inhibitor DEVD-FMK offered significant protection from PB282, but not SW43.

Conclusions

Sigma-2 ligand SW43 commits pancreatic cancer cells to death by a caspase-independent process involving LMP and oxidative stress which is protected from by NAC. PB282 however undergoes a caspase-dependent death following LMP protected by DEVD-FMK and α-toco, which is also known to stabilize the mitochondrial membrane during apoptotic stimuli. These differences in mechanism are likely dependent on the structural class of the compounds versus the inherent sigma-2 binding affinity. As resistance of pancreatic cancers to specific apoptotic stimuli from chemotherapy is better appreciated, and patient-tailored treatments become more available, ligands with high sigma-2 receptor affinity should be chosen based on sensitivities to apoptotic pathways.

【 授权许可】

   
2012 Hornick et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Bowen WD, DeCosta B, Hellewell SB, Thurkauf A, Walker JM, Rice KC: Characterization of [3 H] (+)-pentazocine, a highly selective sigma ligand. Prog Clin Biol Res 1990, 328:117-120.
• [2]Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD: Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994, 268:9-18.
• [3]Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, et al.: Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011, 2:380.
• [4]Mir SU, Ahmed IS, Arnold S, Craven RJ: Elevated Pgrmc1 (progesterone receptor membrane component 1)/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 2011.
• [5]van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA: Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 2010, 16:3519-3537.
• [6]Mach RH, Wheeler KT: Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo. Cent Nerv Syst Agents Med Chem 2009, 9:230-245.
• [7]Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH: Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000, 82:1223-1232.
• [8]Kashiwagi H, McDunn JE, Simon PO, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, et al.: Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 2007, 6:48. BioMed Central Full Text
• [9]Kashiwagi H, McDunn JE, Simon PO, Goedegebuure PS, Vangveravong S, Chang K, Hotchkiss RS, Mach RH, Hawkins WG: Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J Transl Med 2009, 7:24. BioMed Central Full Text
• [10]Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG: The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer 2010, 9:298. BioMed Central Full Text
• [11]Hazelwood S, Bowen WD: Sigma-2 receptor-mediated apoptosis in human SK-N-SH neuroblastoma cells: role of lipid rafts, caspases, and mitochondrial depolarization. Proc Amer Assoc, Cancer Res; 2006:47.
• [12]Crawford KW, Bowen WD: Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002, 62:313-322.
• [13]Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M: Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005, 65:8975-8983.
• [14]Azzariti A, Colabufo NA, Berardi F, Porcelli L, Niso M, Simone GM, Perrone R, Paradiso A: Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol Cancer Ther 2006, 5:1807-1816.
• [15]Colabufo NA, Berardi F, Contino M, Niso M, Abate C, Perrone R, Tortorella V: Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol 2004, 370:106-113.
• [16]Zeng C, Vangveravong S, Jones LA, Hyrc K, Chang KC, Xu J, Rothfuss JM, Goldberg MP, Hotchkiss RS, Mach RH: Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes. Mol Imaging 2011.
• [17]Abate C, Hornick JR, Spitzer D, Hawkins WG, Niso M, Perrone R, Berardi F: Fluorescent Derivatives of sigma Receptor Ligand 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]pipe razine (PB28) as a Tool for Uptake and Cellular Localization Studies in Pancreatic Tumor Cells. J Med Chem 2011, 54:5858-5867.
• [18]D'Souza MP, Ambudkar SV, August JT, Maloney PC: Reconstitution of the lysosomal proton pump. Proc Natl Acad Sci USA 1987, 84:6980-6984.
• [19]Hoekenga MT: The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine. Am J Tro Med Hyg 1954, 3:833-838.
• [20]Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, Kroemer G: Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003, 22:3927-3936.
• [21]Chen JW, Chen GL, D'Souza MP, Murphy TL, August JT: Lysosomal membrane glycoproteins: properties of LAMP-1 and LAMP-2. Biochem Soc Symp 1986, 51:97-112.
• [22]Boya P, Kroemer G: Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451.
• [23]Salganik RI: The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 2001, 20:464S-472S.
• [24]de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van HF: Commentary. Lysosomotropic agents. Biochem Pharmacol 1974, 23:2495-2531.
• [25]Miller DK, Griffiths E, Lenard J, Firestone RA: Cell killing by lysosomotropic detergents. J Cell Biol 1983, 97:1841-1851.
• [26]Drose S, Bindseil KU, Bowman EJ, Siebers A, Zeeck A, Altendorf K: Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry 1993, 32:3902-3906.
• [27]Huss M, Ingenhorst G, Konig S, Gassel M, Drose S, Zeeck A, Altendorf K, Wieczorek H: Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. JBiolChem 2002, 277:40544-40548.
• [28]Firestone RA, Pisano JM, Bonney RJ: Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents. J Med Chem 1979, 22:1130-1133.
• [29]Chen JW, Murphy TL, Willingham MC, Pastan I, August JT: Identification of two lysosomal membrane glycoproteins. J Cell Biol 1985, 101:85-95.
• [30]Carlsson SR, Roth J, Piller F, Fukuda M: Isolation and characterization of human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2. Major sialoglycoproteins carrying polylactosaminoglycan. J Biol Chem 1988, 263:18911-18919.
• [31]Kundra R, Kornfeld S: Asparagine-linked oligosaccharides protect Lamp-1 and Lamp-2 from intracellular proteolysis. J Biol Chem 1999, 274:31039-31046.
• [32]Fehrenbacher N, Bastholm L, Kirkegaard-Sorensen T, Rafn B, Bottzauw T, Nielsen C, Weber E, Shirasawa S, Kallunki T, Jaattela M: Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2. Cancer Res 2008, 68:6623-6633.
• [33]Groth-Pedersen L, Jaattela M: Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett 2010.
• [34]Kirkegaard T, Jaattela M: Lysosomal involvement in cell death and cancer. Biochim Biophys Acta 2009, 1793:746-754.
• [35]Repnik U, Turk B: Lysosomal-mitochondrial cross-talk during cell death. Mitochondrion. 2010, 10:662-669.
• [36]Zhao M, Antunes F, Eaton JW, Brunk UT: Lysosomal enzymes promote mitochondrial oxidant production, cytochrome c release and apoptosis. Eur J Biochem 2003, 270:3778-3786.
• [37]Johansson AC, Appelqvist H, Nilsson C, Kagedal K, Roberg K, Ollinger K: Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 2010, 15:527-540.
• [38]Chow CK, Ibrahim W, Wei Z, Chan AC: Vitamin E regulates mitochondrial hydrogen peroxide generation. Free Radic Biol Med 1999, 27:580-587.
• [39]Post A, Rucker M, Ohl F, Uhr M, Holsboer F, Almeida OF, Michaelidis TM: Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 2002, 26:397-407.
• [40]Berardi F, Colabufo NA, Giudice G, Perrone R, Tortorella V, Govoni S, Lucchi L: New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives. J Med Chem 1996, 39:176-182.
• [41]Abate C, Niso M, Contino M, Colabufo NA, Ferorelli S, Perrone R, Berardi F: 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed sigma and human Delta(8)-Delta(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity. Chem Med Chem 2011, 6:73-80.
• [42]Abate C, Niso M, Lacivita E, Mosier PD, Toscano A, Perrone R: Analogues of sigma receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]pipe razine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers. J Med Chem 2011, 54:1022-1032.
• [43]Ivanova S, Repnik U, Bojic L, Petelin A, Turk V, Turk B: Lysosomes in apoptosis. Methods Enzymol. 2008, 442:183-199.